Eli Lilly v. Compounders: Case-by-Case Outcomes and What They Mean for Patients

Eli Lilly has taken a different litigation posture than Novo Nordisk — more targeted, more focused on tirzepatide compounders selling in bulk or without personalization documentation. The outcomes vary, but a pattern is emerging that patients on compounded tirzepatide should understand.

The Overall Pattern

Lilly's suits against tirzepatide compounders have generally sought two forms of relief: injunctive relief (stopping the compounder from selling tirzepatide products marketed with brand references) and damages for lost sales. Settlements have been the most common outcome, with terms typically involving the compounder agreeing to specific marketing restrictions or to stop compounding tirzepatide in specific configurations.

A smaller number of suits have gone to preliminary injunction hearings. Where courts have granted PIs, they've typically limited the injunction to specific marketing practices rather than blanket compounding bans. Where PIs have been denied, litigation continues on the merits but operations often continue in the interim.

What 'Personalization' Language Looks Like Post-Ruling

After the 503B rulings and Lilly's follow-on litigation, pharmacies that continue to ship compounded tirzepatide have tightened their intake documentation. You'll notice this on new intake forms: explicit questions about excipient allergies, specific dosing needs outside brand strengths, and provider-documented clinical rationale for the compounded formulation. This isn't legal window-dressing — it's the basis on which the pharmacy justifies the compounded product under 503A rules.

If your compounder didn't tighten intake documentation between mid-2025 and now, that's worth asking about. Compounders that haven't updated intake language are exposed in ways that could affect continuity later.

The Oral Tirzepatide Sub-Story

Oral tirzepatide compounding has become a distinct sub-market. Because Lilly's brand tirzepatide (Mounjaro/Zepbound) is injectable-only, the argument for a "meaningful difference" — a key requirement for legal 503A compounding — is stronger for oral formats. Pharmacies compounding oral tirzepatide (tablets, ODTs, drops) have generally faced less litigation pressure than pharmacies compounding injectable formats identical to brand strengths.

This is why you'll see oral tirzepatide at ~$167–$229/month persist even as injectable compounded pricing has shifted. The regulatory footing is different.

Settlement Terms That Affect Patients

When settlements happen, patients rarely see the actual terms — but the operational effects are visible. Common patterns include: the compounder stops shipping to specific states, changes its intake to require additional documentation, drops specific product formats, or agrees to a phased wind-down of a product line. If your compounder announces any of these changes, it's often the visible edge of a private settlement.

Reading the Signal

The Lilly cases suggest a stable post-shortage compounding market for oral tirzepatide, ongoing pressure on injectable tirzepatide compounding, and continued availability where personalization is well-documented. Patients who want stability should either use documented-personalization compounders for injectable, move to oral tirzepatide compounders, or switch to brand-name Zepbound via LillyDirect's cash-pay program (currently in a $299–$449/month range by dose).

Where to Start